Elbasvir and Grazoprevir

Therapeutic indications

Elbasvir and Grazoprevir is indicated for:

Chronic hepatitis C

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Elbasvir/grazoprevir combination is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Elbasvir and Grazoprevir is contraindicated in the following cases:

Lactation

Lactation

Moderate hepatic impairment, severe hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

OATP1B inhibitors

at least one of
Hepatic organic anion transporting polypeptides 1B1 (OATP1B1) inhibitors
Hepatic organic anion transporting polypeptides 1B3 (OATP1B3) inhibitors

CYP3A inducers, P-gp inducers

at least one of
CYP3A4 inducers
Cytochrome P-450 CYP3A5 moderate inducers
Cytochrome P-450 CYP3A5 strong inducers
P-glycoprotein inducers

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: ZEPATIER Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈